Trials / Active Not Recruiting
Active Not RecruitingNCT03995147
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
Phase II Study of Pembrolizumab In Combination With R-CHOP for Patients With Untreated, High-Risk, Non-Germinal Center-Derived DLBCL
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles. Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years). |
| DRUG | R-CHOP Protocol | R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab |
Timeline
- Start date
- 2019-08-29
- Primary completion
- 2027-02-20
- Completion
- 2027-02-20
- First posted
- 2019-06-21
- Last updated
- 2025-06-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03995147. Inclusion in this directory is not an endorsement.